Scientists have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.The study was published in the journal Cell Reports.
"No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo," senior author said. "When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present--it is really the proof-of-concept for a 'functional cure.'"
This new approach is called "Block-and-Lock"--the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Researchers use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
"Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation," senior author said. "It's important to note that our study uses the maximum tolerable dose of the drug--with virtually no side effects."
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
The animal models were exposed to just a single month of treatment. "That's a relatively short period of time," senior author said. "We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We're studying that now."
Because any viral rebound of HIV comes with a host of adverse effects, blocking that rebound would automatically reduce those effects.
http://www.scripps.edu/news/press/2017/20171017valente.html
http://www.cell.com/cell-reports/fulltext/S2211-1247(17)31385-2
"Block-and-Lock" Strategy for HIV-1 Treatment
- 2,598 views
- Added
Edited
Latest News
DNA attached to nanoparticl…
By newseditor
Posted 29 Mar
Neighboring synapses shape…
By newseditor
Posted 29 Mar
Complete vascularization of…
By newseditor
Posted 28 Mar
Immune cells identified as…
By newseditor
Posted 28 Mar
TB blood test which could d…
By newseditor
Posted 27 Mar
Other Top Stories
Role of a scaffold protein in neuro-muscular junction formation
Read more
Role for a protein, IRBIT, in cell death!
Read more
Pregnancy leads to changes in the mother's brain
Read more
Parental obesity linked to delays in child development
Read more
Face recognition part of the brain unexpectedly continues to grow i…
Read more
Protocols
Spatial proteomics in neuro…
By newseditor
Posted 28 Mar
All-optical presynaptic pla…
By newseditor
Posted 23 Mar
Epigenomic tomography for p…
By newseditor
Posted 20 Mar
A mouse DRG genetic toolkit…
By newseditor
Posted 17 Mar
An optogenetic method for t…
By newseditor
Posted 13 Mar
Publications
DNA corona on nanoparticles…
By newseditor
Posted 29 Mar
Co-dependent excitatory and…
By newseditor
Posted 29 Mar
A microfluidic platform int…
By newseditor
Posted 28 Mar
Salmonella manipulates macr…
By newseditor
Posted 28 Mar
BHLHE40/41 regulate microgl…
By newseditor
Posted 28 Mar
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar